- Home
- CANF vs NUAI Comparison
CANF vs NUAI Comparison
Compare CANF & NUAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- NUAI
- Stock Information
- Founded
- CANF 1994
- NUAI N/A
- Country
- CANF Israel
- NUAI United States
- Employees
- CANF N/A
- NUAI N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- NUAI Oil & Gas Production
- Sector
- CANF Health Care
- NUAI Energy
- Exchange
- CANF Nasdaq
- NUAI Nasdaq
- Market Cap
- CANF 9.6M
- NUAI 11.3M
- IPO Year
- CANF N/A
- NUAI N/A
- Fundamental
- Price
- CANF $0.63
- NUAI $0.50
- Analyst Decision
- CANF Strong Buy
- NUAI
- Analyst Count
- CANF 2
- NUAI 0
- Target Price
- CANF $14.00
- NUAI N/A
- AVG Volume (30 Days)
- CANF 140.0K
- NUAI 1.2M
- Earning Date
- CANF 08-26-2025
- NUAI 08-14-2025
- Dividend Yield
- CANF N/A
- NUAI N/A
- EPS Growth
- CANF N/A
- NUAI N/A
- EPS
- CANF N/A
- NUAI N/A
- Revenue
- CANF $560,000.00
- NUAI $718,761.00
- Revenue This Year
- CANF $461.72
- NUAI N/A
- Revenue Next Year
- CANF N/A
- NUAI N/A
- P/E Ratio
- CANF N/A
- NUAI N/A
- Revenue Growth
- CANF N/A
- NUAI 14.80
- 52 Week Low
- CANF $0.63
- NUAI $0.38
- 52 Week High
- CANF $3.12
- NUAI $12.29
- Technical
- Relative Strength Index (RSI)
- CANF 29.23
- NUAI N/A
- Support Level
- CANF $0.64
- NUAI N/A
- Resistance Level
- CANF $0.68
- NUAI N/A
- Average True Range (ATR)
- CANF 0.03
- NUAI 0.00
- MACD
- CANF 0.01
- NUAI 0.00
- Stochastic Oscillator
- CANF 2.00
- NUAI 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).